PTX-100 CTCL Phase 2a study reaches dose optimisation review milestone; on track for December 2026

Announcement highlights:

- 20 evaluable patients enrolled in the ongoing Phase 2a of PTX-100 in cutaneous T-cell lymphoma (CTCL) – 10 evaluable patients in each of the two dosing arms
- This is the pre-specified enrolment threshold for the study's first planned Dose Optimisation Committee (DOC) review – which will convene in December 2026
- The DOC will review data from both dosing arms to provide guidance on continuation of the study for further development
- Reinforces the Company's continued execution against its PTX-100 clinical development timeline
- CEO, James McDonnell will hold an online investor briefing on Friday, 4th September at 11am. Register here: https://prescienttherapeutics.investorportal.com.au/investor-briefing/

MELBOURNE Australia, 02 September 2026: Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, is pleased to announce it has reached the pre-specified enrolment threshold for its first planned Dose Optimisation Committee (DOC) review in its Phase 2a study of PTX-100 in relapsed/refractory cutaneous T-cell lymphoma (CTCL), with 10 evaluable patients now enrolled in each of the study's two dosing arms (20 evaluable patients in total). Patients are considered evaluable on completion of four cycles of treatment.

Reaching this threshold triggers the study's first DOC review, which remains on track to convene in December 2026, consistent with the Company's previously stated timeline.

The DOC, comprising clinical and biostatistical experts, will review safety and efficacy data from both dosing arms of the study to provide guidance on continuation of the study for further development, with an update to the market to follow the DOC's recommendation.

Enrolment in the Phase 2a study continues internationally towards its full target of 40 evaluable patients. The December DOC review is a planned milestone in the study's dose optimisation design, not completion of the study.

PTX-100 has been granted Orphan Drug Designation by the US FDA for all T-cell lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory mycosis fungoides, the most common subtype of CTCL.

“Reaching this first dose optimisation committee meeting reflects strong execution by our clinical team and the sites supporting this study. We look forward to the Dose Optimisation Committee's review in December as we advance PTX-100 towards its next stage of development” said James McDonnell, CEO.

JOIN A BRIEFING

Join CEO, James McDonnell for an online investor briefing on Friday, 4th of September 2026 at 11am (AEST). Register here: https://prescienttherapeutics.investorportal.com.au/investor-briefing/

- ENDS -

The Disclosure Committee of the Board of Prescient Therapeutics Limited has approved the release of this announcement.

For more information please contact:

Company enquiries
James McDonnell
CEO
Prescient Therapeutics
james.mcdonnell@ptxtherapeutics.com

About Prescient Therapeutics Limited (ASX:PTX)

Prescient Therapeutics is a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and advanced cell therapy enhancement platforms.

Targeted Therapy

PTX-100: is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGTase-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is understood to be the only GGTase-1 inhibitor in the world in clinical development. PTX-100 demonstrated safety and early clinical activity in a previous Phase 1 study and recent PK/PD basket study of hematological and solid malignancies. PTX-100 has recently completed a Phase 1b expansion cohort study in T cell lymphomas, where it showed encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T Cell Lymphomas and Fast Track Designation for the treatment of adults with relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. A Phase 2 study in Cutaneous T cell lymphoma (CTCL) is recruiting globally and expects to enrol up to 40 patients in the phase 2a part of the trial.

Cell Therapy Platforms

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets. OmniCAR is in pre-clinical development.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens. OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increases tumour penetration of CAR-T cells. CellPryme-A improves tumour killing and host survival of CAR-T cell therapies, and these benefits are even greater when used in conjunction with CellPryme-M pre-treated CAR-T cells.

CellPryme-M: Prescient's novel, ready-for-the-clinic, CellPryme-M technology enhances adoptive cell therapy performance by shifting T cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumours. CellPryme-M is a 24-hour, non-disruptive process during cell manufacturing. Cell therapies that could benefit from additional productivity in manufacturing or increased potency and durability in-vivo, would be good candidates for CellPryme-M.

Find out more at www.ptxtherapeutics.com or connect with us via LinkedIn.

Forward-Looking Statements

This announcement contains forward-looking statements based on current expectations, estimates, and assumptions. These statements are subject to risks and uncertainties that may cause actual results to differ materially. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this announcement. Prescient undertakes no obligation to revise forward-looking statements except as required by law.